Curr Biol (2015) 25:168293
JonssonBHUvns-MobergKTheorellTGotthardR
In the future, we expect obesity care to become much more differentiated, and with BI 3034701, we aim to go beyond short-term weight loss and address both the biological and behavioral drivers of obesity. BI 3034701 is part of a broader portfolio of therapies being developed for people living with obesity or obesity and connected metabolic health conditions, which has multiple approaches under investigation, including survodutide, a dual glucagon/GLP-1 agonist
In addition to providing a free, no-obligation consultation and a no-win, no-fee guarantee, you can count on us to: Gather and organize evidence to substantiate your claim, including medical records
SOURCE: Annals of Internal Medicine , March 31, 2025 Copyright 2025 HealthDay